BioRegenx Reports Improved Net Loss of $80,565 in Q3 2025 Amid Sales Decline

BioRegenx, Inc. reported a net loss of $80,565 for the third quarter of 2025, a significant improvement compared to a net loss of $394,860 in the same period of 2024. The company’s gross sales for the quarter were $509,532, down 15% from $596,510 in the prior year, leading to net sales of $507,755, a decrease of 15% year-over-year. The decline in sales was attributed to product issues with the medical testing machine, which negatively impacted nutritional sales. Despite the drop in sales, the cost of sales decreased by 29% to $81,358, resulting in a gross profit of $426,397, down 11% from the previous year.

For the nine months ending September 30, 2025, BioRegenx reported a net loss of $525,764, a substantial reduction from a net loss of $4,653,446 for the same period in 2024. Gross sales for the nine-month period were $1,472,806, down 31% from $2,138,993, with net sales decreasing by 22%. The company’s cost of sales also decreased significantly by 48%, leading to a gross profit of $1,184,883, which was 11% lower than the previous year. The reduction in losses and costs was primarily due to decreased distributor incentives and a significant reduction in selling, general, and administrative expenses, which fell by 63% to $1,454,635.

Operationally, BioRegenx has undergone significant changes, including the acquisition of DocSun Biomedical Holdings, Inc. in January 2024, which was accounted for as an asset acquisition. The company also completed a merger with Findit, Inc. in March 2024, which resulted in a change of control and a new corporate structure. As of September 30, 2025, the company had 961,992,601 shares of common stock outstanding, reflecting a slight increase from the previous year. The company’s employee headcount and customer engagement metrics were not disclosed in the filing.

Looking ahead, BioRegenx faces challenges related to its liquidity and capital resources. The company reported cash and cash equivalents of $46,947 as of September 30, 2025, down from $70,081 a year earlier. The company has indicated that it will need to secure additional financing to continue operations and fund its business development plans. Management has expressed substantial doubt about the company’s ability to continue as a going concern, given its recurring losses and cash flow deficits. The company is actively pursuing options for debt or equity financing but has not guaranteed that such financing will be available or sufficient to meet its needs.